Compare Fortinet Inc (FTNT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Fortinet Inc trades at $181.55 (market cap $135.04B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Fortinet Inc is far larger — about 18.4× Spyre Therapeutics Inc. Common Stock's market cap, and Fortinet Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FTNT | SYRE | |
|---|---|---|
Market Cap | $135.04B | $7.35B |
Volume | 3,955,126 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $194.75 | $108.92 |
52-Week Low | $75.23 | $22.18 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $131.47B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $190.76, down 1.13% on the day but remains in a bullish technical trend with strong support near $191. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.90 surpassing the $0.746 estimate. Revenue growth is steady, reaching $6.80B in 2025, while profitability metrics like a 28.17% net income margin and 117.44% ROE highlight operational efficiency. Recent news highlights AI-driven cybersecurity demand and a 52-week high, reflecting positive momentum.
The outlook for FTNT is positive, driven by cybersecurity tailwinds and superior product economics, but high valuation ratios (P/E of 67.41, P/S of 18.95) pose risks if growth slows. Analyst consensus is mixed with 42% buy ratings, and the stock trades above the $160.24 price target, suggesting limited near-term upside. Key risks include competitive pressures and execution challenges in sustaining high growth rates.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
